Inclusion Criteria:

- Femal patient aged > 18 years

- Histologically proven breast adenocarcinoma

- HER2 negative receptors

- previously received first or second line chemotherapy for metastatic disease

- previously treated with anthracycline and/or docetaxel in adjuvant and/or as first or
second line therapy

- presence of one or several evaluable metastatic lesion(s)

- presence of at least one target lesion not previously irradiated

- previously treated with hormonotherapy in adjuvant or in metastatic line (treatment
will be ceased upon patient registration in the study)

- ECOG Performance status < 2

- adequate biological values

- patient who has clearly given her consent by signing on informed consent form prior
to participation

Exclusion Criteria:

- patient previously treated with paclitaxel or capecitabine for metastatic breast
cancer

- patient with only local metastatic disease (with the exception of axillary lymph
nodes)

- active symptomatic brain metastasis

- patient with an history of significant cardiovascular impairment (congestive heart
failure> NYHA grade II, unstable angina or myocardial infraction within the past six
months or serious cardiac arrhythmia)

- peripheric neuropathy grade ≥ 2

- history of another malignancy within past 5 years that could confound diagnosis or
staging of breast cancer (with the exception of in situ cacinoma of the cervix or
adequately treated basel cell carcinoma of the skin)

- patient with any medical or psychiatric condition that, in the opinion of the
Principal Investigator, would preclude her from participating in this study

- patient with a known allergy to one or several of the study compounds

- patients who may not be regularly available due to geographical, social or family
reasons

- history of renal, hepatic or metabolic pathology that could preclude with metabolism
or elimination of the study product

- deficiencies of the upper intestinal tract, malabsorption syndrome

- patient who is pregnant, breast-feeding or using inadequate contraception